【摘要】 目的:探讨骨髓增生异常综合征(MDS)患者骨髓中HOXA9基因和蛋白的表达模式及其与诊断、治疗的关系。方法:应用流式细胞术检测33例MDS患者、12例初治急性髓系白血病、20例免疫性血小板减少性紫癜和18名正常对照者的骨髓样本的HOXA9蛋白水平,利用实时荧光定量PCR检测HOXA9 mRNA的表达水平。结果:MDS患者HOXA9~+/CD34~+和HOXA9~+/CD34~+CD38~-比例均高于对照组(P<0.05)。HOXA9的mRNA相对表达量与蛋白水平相一致。未行地西他滨治疗的患者HOXA9~+/CD34~+为(50.64±27.59)%,HOXA9~+/CD34~+CD38~-为(55.67±28.57)%,均高于正常对照组(P<0.05)。经地西他滨治疗患者的HOXA9~+/CD34~+和HOXA9~+/CD34~+CD38~-比例均低于未治组(P<0.05)。结论:HOXA9在MDS中异常高表达且与相关临床特征有相关,提示HOXA9在MDS诊治中具有指导意义。更多还原

【Abstract】 Objective:To investigate the expression pattern of HOXA9 in myelodysplastic syndrome(MDS) patients and its relation with clinical characteristics and treatment response.Methods:The mRNA and protein expression levels of HOXA9 in bone marrow cells from 33 cases of MDS,12 cases of AML,20 cases of ITP and 18 normal controls were detected by real-time guautitative PCR(RT-PCR) and flow cytometry,respectively.Results:The percentage of HOXA9~+/CD34~+ and HOXA9~+/CD34~+ CD38~-in MDS patients were significantly higher than that in control group(P<0.05),and the mRNA and protein expression of HOXA9 in MDS patients had a similar trend.The percentages of HOXA9~+/CD34~+ and HOXA9~+/CD34~+ CD38~-before decitabine treatment were(50.64 ± 27.59)%and(55.67 ±28.57)%respectively,which were both higher than those in control group(P < 0.05).After decitabine treatment,expression of HOXA9 significantly decreased(P <0.05).Conclusion:HOXA9 is overexpressed in MDS patients and associated with several clinical characteristics.The detection of HOXA9 expression may have guide roles for diagnosis and treatment of MDS patients.更多还原